In vitro models of TGF-β-induced fibrosis suitable for high-throughput screening of antifibrotic agents

American Journal of Physiology - Renal Physiology

Volumn 293, Issue 2, 2007, Pages

  Xu, Qihe ^a,b   Norman, Jill T ^b   Shrivastav, Shashi ^a   Lucio Cazana, Javier ^c   Kopp, Jeffrey B ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

Cell migration; Collagen; Fibronectin; Smad3; Tranilast

Indexed keywords

ANTIFIBROTIC AGENT; COLLAGEN; MATRIX PROTEIN; POLYLYSINE; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CELL GROWTH; CELL MIGRATION; CONTROLLED STUDY; CULTURE MEDIUM; FIBROBLAST; FIBROGENESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY FIBROSIS; MESANGIUM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPECTROPHOTOMETRY;

EID: 34548415872     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00379.2006     Document Type: Article

References (45)

1. Abrass CK, Spicer D, Raugi GJ. Induction of nodular sclerosis by insulin in rat mesangial cells in vitro: studies of collagen. Kidney Int 47: 25-37, 1995.
2. Ayo SH, Kreisberg JI. Heparin increases hillock formation in mesangial cell cultures. J Am Soc Nephrol 2: 1153-1157, 1991.
3. Branton MH, Kopp JB. TGF-beta and fibrosis. Microbes Infect 1: 1349-1365, 1999.
4. Breitkopf K, Haas S, Wiercinska E, Singer MV, Dooley S. Anti-TGF-beta strategies for the treatment of chronic liver disease. Alcohol Clin Exp Res 29: 121S-131S, 2005.
5. Brown KK, Raghu G. Medical treatment for pulmonary fibrosis: current trends, concepts, and prospects. Clin Chest Med 25: 759-772, 2004.
6. Butcher EC, Berg EL, Kunkel EJ. Systems biology in drug discovery. Nat Biotechnol 22: 1253-1259, 2004.
7. Chatziantoniou C, Dussaule JC. Insights into the mechanisms of renal fibrosis: is it possible to achieve regression? Am J Physiol Renal Physiol 289: F227-F234, 2005.
8. Clouthier DE, Comerford SA, Hammer RE. Hepatic fibrosis, glomerulosclerosis, and a lipodystrophy-like syndrome in PEPCK-TGF-beta1 transgenic mice. J Clin Invest 100: 2697-2713, 1997.
9. de Gouville AC, Boullay V, Krysa G, Pilot J, Brusq JM, Loriolle F, Gauthier JM, Papworth SA, Laroze A, Gellibert F, Huet S. Inhibition of TGF-beta signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine- induced liver fibrosis. Br J Pharmacol 145: 166-177, 2005.
10. Eitner F, Floege J. Therapeutic targets for prevention and regression of progressive fibrosing renal diseases. Curr Opin Investig Drugs 6: 255-261, 2005.
11. Flanders KC. Smad3 as a mediator of the fibrotic response. Int J Exp Pathol 85: 47-64, 2004.
12. Gellibert F, de Gouville AC, Woolven J, Mathews N, Nguyen VL, Bertho-Ruault C, Patikis A, Grygielko ET, Laping NJ, Huet S. Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor. J Med Chem 49: 2210-2221, 2006.
13. Gellibert F, Woolven J, Fouchet MH, Mathews N, Goodland H, Lovegrove V, Laroze A, Nguyen VL, Sautet S, Wang R, Janson C, Smith W, Krysa G, Boullay V, De Gouville AC, Huet S, Hartley D. Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors. J Med Chem 47: 4494-4506, 2004.
14. Gimbrone MA Jr, Cotran RS. Human vascular smooth muscle in culture. Growth and ultrastructure. Lab Invest 33: 16-27, 1975.
15. Glass WF 2nd, Teng PR, Haney LB. Extracellular matrix distribution and hillock formation in human mesangial cells in culture without serum. J Am Soc Nephrol 7: 2230-2243, 1996.
16. Grimm PC, Nickerson P, Gough J, McKenna R, Stern E, Jeffery J, Rush DN. Computerized image analysis of Sirius Red-stained renal allograft biopsies as a surrogate marker to predict long-term allograft function. J Am Soc Nephrol 14: 1662-1668. 2003.
17. Harper PA, Juliano RL. Isolation and characterization of Chinese hamster ovary cell variants defective in adhesion to fibronectin-coated collagen. J Cell Biol 87: 755-763, 1980.
18. Heeneman S, Cleutjens JP, Faber BC, Creemers EE, van Suylen RJ, Lutgens E, Cleutjens KB, Daemen MJ. The dynamic extracellular matrix: intervention strategies during heart failure and atherosclerosis. J Pathol 200: 516-525, 2003.
19. Ihn H. Scleroderma, fibroblasts, signaling, and excessive extracellular matrix. Curr Rheumatol Rep 7: 156-162, 2005.
20. Jackson PD, Harrington JJ. High-throughput target discovery using cell-based genetics. Drug Discov Today 10: 53-60, 2005.
21. Kitamura M. The antioxidant N-acetylcysteine induces mesangial cells to create three-dimensional cytoarchitecture that underlies cellular differentiation. J Am Soc Nephrol 10: 746-751, 1999.
22. Kitamura M, Mitarai T, Nagasawa R, Maruyama N. Differentiated phenotype of glomerular mesangial cells in nodular culture. Am J Physiol Renal Fluid Electrolyte Physiol 270: F614-F622, 1996.
23. Kopp JB, Factor VM, Mozes M, Nagy P, Sanderson N, Bottinger EP, Klotman PE, Thorgeirsson SS. Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. Lab Invest 74: 991-1003, 1996.
24. Lan HY. Tubular epithelial-myofibroblast transdifferentiation mechanisms in proximal tubule cells. Curr Opin Nephrol Hypertens 12: 25-29, 2003.
25. Laping NJ, Grygielko E, Mathur A, Butter S, Bomberger J, Tweed C, Martin W, Fornwald J, Lehr R, Harling J, Gaster L, Callahan JF, Olson BA. Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542. Mol Pharmacol 62: 58-64, 2002.
26. Liu XJ, Ruan CM, Gong XF, Li XZ, Wang HL, Wang MW, Yin JQ. Antagonism of transforming growth factor-Beta signaling inhibits fibrosis-related genes. Biotechnol Lett 27: 1609-1615, 2005.
27. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 69: 213-217, 2006.
28. Manzano VM, Munoz JC, Jimenez JR, Puyol MR, Puyol DR, Kitamura M, Cazana FJ. Human renal mesangial cells are a target for the anti-inflammatory action of 9-cis retinoic acid. Br J Pharmacol 131: 1673-1683, 2000.
29. Mattana J, Jaffer S, Singhal PC. Effects of macrophage supernatants on mesangial cell migration and hillock formation. Proc Soc Exp Biol Med 208: 271-276, 1995.
30. May JF, Paule WJ, Rounds DE, Blankenhorn DH, Zemplenyi T. The induction of atherosclerotic plaque-like mounds in cultures of aortic smooth muscle cells. Virchows Arch B Cell Pathol 18: 205-211, 1975.
31. Muller GA, Rodemann HP. Characterization of human renal fibroblasts in health and disease. I. Immunophenotyping of cultured tubular epithelial cells and fibroblasts derived from kidneys with histologically proven interstitial fibrosis. Am J Kidney Dis 17: 680-683, 1991.
32. Pancre V, Delacre M, Herno J, Auriault C. Schistosomal egg antigenresponsive CD8 T-cell population in Schistosoma mansoni-infected BALB/c mice. Immunology 98: 525-534, 1999.
33. Pfab T, Hocher B. Tranilast and hypertensive heart disease: further insights into mechanisms of an anti-inflammatory and anti-fibrotic drug. J Hypertens 22: 883-886, 2004.
34. Phillips AO, Steadman R. Diabetic nephropathy: the central role of renal proximal tubular cells in tubulointerstitial injury. Histol Histopathol 17: 247-252, 2002.
35. Ruan XZ, Varghese Z, Powis SH, Moorhead JF. Dysregulation of LDL receptor under the influence of inflammatory cytokines: a new pathway for foam cell formation. Kidney Int 60: 1716-1725, 2001.
36. Saleem MA, O'Hare MJ, Reiser J, Coward RJ, Inward CD, Farren T, Xing CY, Ni L, Mathieson PW, Mundel P. A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J Am Soc Nephrol 13: 630-638, 2002.
37. Sanderson N, Factor V, Nagy P, Kopp J, Kondaiah P, Wakefield L, Roberts AB, Sporn MB, Thorgeirsson SS. Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci USA 92: 2572-2576, 1995.
38. Sawyer JS, Anderson BD, Beight DW, Campbell RM, Jones ML, Herron DK, Lampe JW, McCowan JR, McMillen WT, Mort N, Parsons S, Smith EC, Vieth M, Weir LC, Yan L, Zhang F, Yingling JM. Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. J Med Chem 46: 3953-3956, 2003.
39. Shime H, Kariya M, Orii A, Momma C, Kanamori T, Fukuhara K, Kusakari T, Tsuruta Y, Takakura K, Nikaido T, Fujii S. Tranilast inhibits the proliferation of uterine leiomyoma cells in vitro through G1 arrest associated with the induction of p21(waf1) and p53. J Clin Endocrinol Metab 87: 5610-5617, 2002.
40. Soma J, Sugawara T, Huang YD, Nakajima J, Kawamura M. Tranilast slows the progression of advanced diabetic nephropathy. Nephron 92: 693-698, 2002.
41. Sraer JD, Delarue F, Hagege J, Feunteun J, Pinet F, Nguyen G, Rondeau E. Stable cell lines of T-SV40 immortalized human glomerular mesangial cells. Kidney Int 49: 267-270, 1996.
42. Sterzel RB, Lovett DH, Foellmer HG, Perfetto M, Biemesderfer D, Kashgarian M. Mesangial cell hillocks. Nodular foci of exaggerated growth of cells and matrix in prolonged culture. Am J Pathol 125: 130-140, 1986.
43. Tamai H, Katoh K, Yamaguchi T, Hayakawa H, Kanmatsuse K, Haze K, Aizawa T, Nakanishi S, Suzuki S, Suzuki T, Takase S, Nishikawa H, Katoh O. The impact of tranilast on restenosis after coronary angioplasty: the Second Tranilast Restenosis Following Angioplasty Trial (TREAT-2). Am Heart J 143: 506-513, 2002.
44. Wynn TA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 4: 583-594, 2004.
45. Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov 3: 1011-1022, 2004.